Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
STML After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.32%90.401.3%$812.42m
AMGNAmgen Inc.
-0.03%186.921.2%$635.34m
GILDGilead Sciences, Inc.
0.33%66.980.9%$508.19m
BIIBBiogen Inc.
0.65%335.161.3%$445.14m
ILMNIllumina, Inc.
-0.01%302.243.5%$320.02m
REGNRegeneron Pharmaceuticals, Inc.
0.45%422.512.6%$304.29m
VRTXVertex Pharmaceuticals Incorporated
0.52%187.841.9%$269.00m
ALXNAlexion Pharmaceuticals, Inc.
0.71%129.842.0%$236.61m
SRPTSarepta Therapeutics, Inc.
0.22%140.5715.4%$155.25m
AAgilent Technologies, Inc.
1.28%78.511.6%$145.08m
EXASExact Sciences Corporation
-2.27%83.6325.3%$129.45m
INCYIncyte Corporation
-0.40%83.742.5%$115.31m
ARRYArray BioPharma Inc.
0.30%23.178.2%$109.81m
EXELExelixis, Inc.
-0.52%21.246.4%$84.04m
NBIXNeurocrine Biosciences, Inc.
-1.89%79.365.1%$80.57m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.